2016
Effect of Neoadjuvant Chemoradiotherapy on Pathologic Stage and Survival in Patients with Locally Advanced Esophageal Cancer
L K, B B, A F, RF H, E H, MK G. Effect of Neoadjuvant Chemoradiotherapy on Pathologic Stage and Survival in Patients with Locally Advanced Esophageal Cancer. Journal Of Cancer Science And Clinical Oncology 2016, 3 DOI: 10.15744/2394-6520.3.105.Peer-Reviewed Original Research
2014
Increased Time From Neoadjuvant Chemoradiation to Surgery Is Associated With Higher Pathologic Complete Response Rates in Esophageal Cancer
Shaikh T, Ruth K, Scott WJ, Burtness BA, Cohen SJ, Konski AA, Cooper HS, Astsaturov I, Meyer JE. Increased Time From Neoadjuvant Chemoradiation to Surgery Is Associated With Higher Pathologic Complete Response Rates in Esophageal Cancer. The Annals Of Thoracic Surgery 2014, 99: 270-276. PMID: 25440267, PMCID: PMC4284823, DOI: 10.1016/j.athoracsur.2014.08.033.Peer-Reviewed Original ResearchConceptsPathologic complete response rateComplete response rateHigher pathologic complete response rateNeoadjuvant chemoradiationResponse rateEsophageal cancerNeoadjuvant chemoradiation treatmentCompletion of chemoradiationTiming of surgeryLength of stayOperative stayChemoradiation treatmentBlood lossPathologic responseSurgery intervalSurgical morbidityCancer sitesChemoradiationMorbidity dataSurgeryPatientsInterval groupTreatment factorsEsophagectomyStayFreedom from recurrence after induction cisplatin/5-FU/RT versus carboplatin/paclitaxel/RT in patients with esophageal cancer.
Thomay A, Su S, Friedant A, Ruth K, Astsaturov I, Burtness B, Denlinger C, Dotan E, Hall M, Meyer J, Shah P, Cohen S, Scott W. Freedom from recurrence after induction cisplatin/5-FU/RT versus carboplatin/paclitaxel/RT in patients with esophageal cancer. Journal Of Clinical Oncology 2014, 32: 126-126. DOI: 10.1200/jco.2014.32.3_suppl.126.Peer-Reviewed Original ResearchEsophageal cancerOverall survivalGroup BLandmark analysisGroup ANeoadjuvant treatment regimenKaplan-Meier methodEsophageal cancer patientsProspective databaseR0 resectionDistant recurrencePatient demographicsSurgery patientsMeier methodMore recurrencesOperative complicationsPathologic responseTreatment regimenCancer patientsOperative procedurePatientsLarge seriesRecurrenceSurvival curvesPropensity score
2013
Esophageal carcinoma
Boland PM, Burtness B. Esophageal carcinoma. Current Opinion In Oncology 2013, 25: 417-424. PMID: 23680713, DOI: 10.1097/cco.0b013e328362105e.Peer-Reviewed Original ResearchConceptsEsophageal cancerT-lymphocyte antigen-4Platinum-based regimensSubgroup of patientsVascular endothelial growth factorGrowth factor 1 receptorImproved patient selectionEndothelial growth factorEpidermal growth factor receptorMinimal additional benefitFactor 1 receptorProminent molecular targetsGrowth factor receptorStandard cytotoxicChemotherapeutic regimenSurvival benefitPatient selectionEsophagogastric junctionTherapeutic regimensAntigen-4Esophageal carcinomaClinical investigationEncouraging dataMulticenter effortsEarly benefits
2012
Effect of increased time from chemoradiation to surgery on the pathologic complete response rate in patients with esophageal cancer.
Shaikh T, Ruth K, Scott W, Burtness B, Cohen S, Konski A, Cooper H, Astsaturov I, Meyer J. Effect of increased time from chemoradiation to surgery on the pathologic complete response rate in patients with esophageal cancer. Journal Of Clinical Oncology 2012, 30: 84-84. DOI: 10.1200/jco.2012.30.4_suppl.84.Peer-Reviewed Original ResearchPathologic complete responseEsophageal cancerPathologic complete response rateT3/T4 lesionsT1/T2 lesionsCarboplatin-based therapyTri-modality treatmentComplete response rateMedian radiation doseType of chemotherapyResectable esophageal cancerMultivariable logistic regressionSquamous cell carcinomaRadiation doseEnd of chemoradiationTrimodality therapyDistant recurrenceSubsequent surgeryT4 lesionsComplete responseMedian ageRectal cancerT2 lesionsMedian timeMultivariable analysis
2009
Phase II trial of docetaxel–irinotecan combination in advanced esophageal cancer
Burtness B, Gibson M, Egleston B, Mehra R, Thomas L, Sipples R, Quintanilla M, Lacy J, Watkins S, Murren JR, Forastiere AA. Phase II trial of docetaxel–irinotecan combination in advanced esophageal cancer. Annals Of Oncology 2009, 20: 1242-1248. PMID: 19429872, PMCID: PMC2699385, DOI: 10.1093/annonc/mdn787.Peer-Reviewed Original ResearchConceptsAdvanced esophageal cancerPartial responseComplete responseEligible patientsEsophageal cancerEastern Cooperative Oncology Group performance statusMetastatic squamous cell carcinomaSafety of docetaxelPhase II trialSquamous cell carcinomaPrincipal toxic effectsAssessable patientsEsophagogastric cancerMeasurable diseaseToxic deathsII trialCN patientsMedian survivalPerformance statusNormal bilirubinPreclinical evidenceMedian timeCell carcinomaMyocardial infarctionTumor assessment
2005
Phase II trial of docetaxel/irinotecan therapy in metastatic esophageal cancer: evidence for activity in previously untreated patients
Burtness B, Gibson M, Lacy J, Rowen E, Thomas L, Sipples R, McGurk M, Murren J, Forastiere A. Phase II trial of docetaxel/irinotecan therapy in metastatic esophageal cancer: evidence for activity in previously untreated patients. Journal Of Clinical Oncology 2005, 23: 4070-4070. DOI: 10.1200/jco.2005.23.16_suppl.4070.Peer-Reviewed Original Research
2004
Effect of neoadjuvant chemoradiotherapy on pathologic stage and survival in patients with locally advanced esophageal cancer
Gibson M, Burtness B, Heath E, Heitmiller R, Forastiere A. Effect of neoadjuvant chemoradiotherapy on pathologic stage and survival in patients with locally advanced esophageal cancer. Journal Of Clinical Oncology 2004, 22: 4032-4032. DOI: 10.1200/jco.2004.22.14_suppl.4032.Peer-Reviewed Original ResearchEffect of neoadjuvant chemoradiotherapy on pathologic stage and survival in patients with locally advanced esophageal cancer
Gibson M, Burtness B, Heath E, Heitmiller R, Forastiere A. Effect of neoadjuvant chemoradiotherapy on pathologic stage and survival in patients with locally advanced esophageal cancer. Journal Of Clinical Oncology 2004, 22: 4032-4032. DOI: 10.1200/jco.2004.22.90140.4032.Peer-Reviewed Original Research
2003
Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy.
Gibson MK, Abraham SC, Wu TT, Burtness B, Heitmiller RF, Heath E, Forastiere A. Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clinical Cancer Research 2003, 9: 6461-8. PMID: 14695149.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedBcl-2-Associated X ProteinCisplatinCombined Modality TherapyDisease-Free SurvivalDNA Mutational AnalysisErbB ReceptorsEsophageal NeoplasmsFemaleFluorouracilGenes, p53HumansImmunohistochemistryMaleMiddle AgedMutationProportional Hazards ModelsProto-Oncogene ProteinsProto-Oncogene Proteins c-bcl-2Regression AnalysisTime FactorsTreatment OutcomeConceptsAdvanced esophageal cancerOverall survivalComplete responseEsophageal cancerEpidermal growth factor receptorP53 mutationsGrowth factor receptorClinical covariatesCellular markersBetter tumor differentiationPathological complete responseFactor receptorEGF-R expressionBcl-2 expressionInfusional cisplatinDaily radiotherapyMost patientsPoor OSPreoperative chemoradiotherapyPatient agePretreatment tumorOutcome predictorsPredictive factorsBarrett's metaplasiaTumor locationMature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer
Kleinberg L, Knisely JP, Heitmiller R, Zahurak M, Salem R, Burtness B, Heath EI, Forastiere AA. Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer. International Journal Of Radiation Oncology • Biology • Physics 2003, 56: 328-334. PMID: 12738305, DOI: 10.1016/s0360-3016(02)04598-4.Peer-Reviewed Original ResearchConceptsTime of surgeryEsophageal cancerDay 1Survival rateNeoadjuvant therapyPreoperative therapyMedian survivalComplete responseVenous infusionSurvival resultsResponse rateDisease-specific survival ratesLong-term survival resultsPathologic complete response rateCycles of paclitaxelPathologic stage IIAComplete response ratePathologic complete responsePathologic stage IRemainder of patientsDisease-specific survivalOverall cure rateSquamous cell carcinomaIsolated local failureCancer-related death
1999
83 Long term local control and survival with preoperative cisplatin, continuous infusion 5-FU, and 45 Gy radiotherapy for esophageal cancer
Kleinberg L, Knisley J, Heitmiller R, Yang S, Zahurak M, Salem R, Burtness B, Heath E, Forastiere A. 83 Long term local control and survival with preoperative cisplatin, continuous infusion 5-FU, and 45 Gy radiotherapy for esophageal cancer. International Journal Of Radiation Oncology • Biology • Physics 1999, 45: 189-190. DOI: 10.1016/s0360-3016(99)90101-3.Peer-Reviewed Original Research